Regulation of SHP2 by PTEN/AKT/GSK-3β signaling facilitates IFN-γ resistance in hyperproliferating gastric cancer.

Oncogenic activation accompanied by escape from immune surveillance, such as IFN-γ resistance, is critical for cancer cell growth and survival. In this study, we investigated the crosstalk signaling between IFN-γ resistance and signaling of hyperproliferation in gastric cancer cells. IFN-γ inhibited the cell growth of MKN45 cells but not hyperproliferating AGS cells. AGS cells did not respond to IFN-γ because of a decrease in STAT1 but not due to dysfunctional IFN-γ receptors. Signaling of PI3K/AKT, as well as MEK/ERK, was required for the hyperproliferation; notably, PI3K/AKT alone mediated the IFN-γ resistance. Aberrant Src homology-2 domain-containing phosphatase (SHP) 2 determined IFN-γ resistance but unexpectedly had no effects on hyperproliferation or ERK activation. In the IFN-γ resistant cells, inactivation of glycogen synthase kinase (GSK)-3β by PI3K/AKT was important for SHP2 activation but not for hyperproliferation. An imbalance of AKT/GSK-3β/SHP2 caused by a reduction of PTEN was important for the crosstalk between IFN-γ resistance and hyperproliferation. PI3K is constitutively expressed in AGS cells and immunohistochemical staining showed a correlation between hyperproliferation and expression of SHP2 and STAT1 in gastric tumors. These results demonstrate the effects of PTEN/AKT/GSK-3β/SHP2 signaling on IFN-γ resistance in hyperproliferating gastric cancer cells.

[1]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[2]  Carlos Resende,et al.  Genetic and Epigenetic Alteration in Gastric Carcinogenesis , 2010, Helicobacter.

[3]  M. Katoh,et al.  Dysregulation of stem cell signaling network due to germline mutation, SNP, helicobacter pylori infection, epigenetic change, and genetic alteration in gastric cancer , 2007, Cancer biology & therapy.

[4]  I. Julkunen,et al.  Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. , 1997, Journal of immunology.

[5]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[6]  M. Oshimura,et al.  PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.

[7]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[8]  D. Green,et al.  Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. , 2006, Molecular cell.

[9]  Takeshi Azuma,et al.  Helicobacter pylori CagA Induces Ras-independent Morphogenetic Response through SHP-2 Recruitment and Activation* , 2004, Journal of Biological Chemistry.

[10]  O. Sokolova,et al.  Helicobacter pylori Suppresses Glycogen Synthase Kinase 3β to Promote β-Catenin Activity* , 2008, Journal of Biological Chemistry.

[11]  Stephen L. Abrams,et al.  Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. , 2006, Advances in enzyme regulation.

[12]  G. Feng,et al.  PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. , 2007, Blood.

[13]  G. Klein,et al.  Cancer, apoptosis, and nonimmune surveillance , 2004, Cell Death and Differentiation.

[14]  Yee‐Shin Lin,et al.  Glycogen Synthase Kinase-3β Facilitates IFN-γ-Induced STAT1 Activation by Regulating Src Homology-2 Domain-Containing Phosphatase 21 , 2009, The Journal of Immunology.

[15]  Yee‐Shin Lin,et al.  Autophagy Facilitates IFN-γ-induced Jak2-STAT1 Activation and Cellular Inflammation* , 2010, The Journal of Biological Chemistry.

[16]  A. Ray,et al.  Glycogen synthase kinase 3: more than a namesake , 2009, British journal of pharmacology.

[17]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[18]  F. Garrido,et al.  Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line , 1998, Cancer Immunology, Immunotherapy.

[19]  L. Ellis,et al.  Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model , 2007, International journal of cancer.

[20]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[21]  S. Maher,et al.  Clinical Use of Interferon‐γ , 2009, Annals of the New York Academy of Sciences.

[22]  Hermann Brenner,et al.  Epidemiology of stomach cancer. , 2009, Methods in molecular biology.

[23]  H. Huynh,et al.  Helicobacter pylori Disrupts STAT1-Mediated Gamma Interferon-Induced Signal Transduction in Epithelial Cells , 2004, Infection and Immunity.

[24]  Khean Lee Goh,et al.  Screening for gastric cancer in Asia: current evidence and practice. , 2008, The Lancet. Oncology.

[25]  Joel Moss,et al.  Helicobacter pylori VacA-induced Inhibition of GSK3 through the PI3K/Akt Signaling Pathway* , 2009, Journal of Biological Chemistry.

[26]  E. Krebs,et al.  Inactivation of Glycogen Synthase Kinase-3 by Epidermal Growth Factor Is Mediated by Mitogen-activated Protein Kinase/p90 Ribosomal Protein S6 Kinase Signaling Pathway in NIH/3T3 Cells (*) , 1995, The Journal of Biological Chemistry.

[27]  M. Hatakeyama.  Oncogenic mechanisms of the Helicobacter pylori CagA protein , 2004, Nature Reviews Cancer.

[28]  Dung-Fang Lee,et al.  Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. , 2007, Cancer research.

[29]  K. Shuai,et al.  Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.

[30]  Hiroyuki Takahashi,et al.  Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas. , 2010, Human pathology.

[31]  G. Tamura.  Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. , 2006, World journal of gastroenterology.

[32]  H. Lee,et al.  Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[33]  G. Feng,et al.  Shp-2 Tyrosine Phosphatase Functions as a Negative Regulator of the Interferon-Stimulated Jak/STAT Pathway , 1999, Molecular and Cellular Biology.

[34]  H. Ljunggren,et al.  Escape from immune- and nonimmune-mediated tumor surveillance. , 2006, Seminars in cancer biology.

[35]  K. Shuai,et al.  The Suppressor of Cytokine Signaling (SOCS) 1 and SOCS3 but Not SOCS2 Proteins Inhibit Interferon-mediated Antiviral and Antiproliferative Activities* , 1998, The Journal of Biological Chemistry.

[36]  B. Neel,et al.  The tyrosine phosphatase Shp2 (PTPN11) in cancer , 2008, Cancer and Metastasis Reviews.

[37]  T. Azuma,et al.  The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. , 2003, The Journal of infectious diseases.

[38]  A. Carnero.  The PKB/AKT pathway in cancer. , 2010, Current pharmaceutical design.